IL134716A0 - Treatment of oppositional defiant disorder - Google Patents

Treatment of oppositional defiant disorder

Info

Publication number
IL134716A0
IL134716A0 IL13471698A IL13471698A IL134716A0 IL 134716 A0 IL134716 A0 IL 134716A0 IL 13471698 A IL13471698 A IL 13471698A IL 13471698 A IL13471698 A IL 13471698A IL 134716 A0 IL134716 A0 IL 134716A0
Authority
IL
Israel
Prior art keywords
treatment
oppositional defiant
defiant disorder
disorder
oppositional
Prior art date
Application number
IL13471698A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL134716A0 publication Critical patent/IL134716A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13471698A 1997-09-23 1998-09-01 Treatment of oppositional defiant disorder IL134716A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5962997P 1997-09-23 1997-09-23
PCT/US1998/018114 WO1999015176A1 (en) 1997-09-23 1998-09-01 Treatment of oppositional defiant disorder

Publications (1)

Publication Number Publication Date
IL134716A0 true IL134716A0 (en) 2001-04-30

Family

ID=22024203

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13471698A IL134716A0 (en) 1997-09-23 1998-09-01 Treatment of oppositional defiant disorder

Country Status (17)

Country Link
US (1) US6028070A (ru)
EP (1) EP0919236A1 (ru)
JP (1) JP2001517627A (ru)
KR (1) KR20010024218A (ru)
CN (1) CN1146412C (ru)
AU (1) AU740109B2 (ru)
BR (1) BR9812357A (ru)
CA (1) CA2304115A1 (ru)
EA (1) EA002689B1 (ru)
HU (1) HUP0003591A3 (ru)
IL (1) IL134716A0 (ru)
NO (1) NO20001458L (ru)
NZ (1) NZ502810A (ru)
PL (1) PL339426A1 (ru)
TR (1) TR200000755T2 (ru)
UA (1) UA56257C2 (ru)
WO (1) WO1999015176A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052531A1 (en) 1998-04-09 1999-10-21 Pharmacia & Upjohn Company New treatments for nervous disorders
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
EP1500395B1 (en) * 1999-07-01 2006-03-08 Pharmacia & Upjohn Company LLC Reboxetine for treating fibromyalgia and other somatoform disorders
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
CO5210862A1 (es) * 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
CN1407890A (zh) * 2000-03-07 2003-04-02 伊莱利利公司 牛皮癣的治疗
EP1383465B1 (en) * 2001-03-29 2011-08-10 Michael Davis Acute pharmacologic augmentation of psychotherapy with d-cycloserine
US6613763B2 (en) 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
CA2481934A1 (en) * 2002-04-18 2003-10-30 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
AU2003243172A1 (en) * 2002-04-29 2003-11-17 Alza Corporation Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation
BR0311878A (pt) * 2002-06-17 2005-04-05 Pharmacia Italia Spa Sais farmacêuticos de reboxetina
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
PT1601349E (pt) * 2003-02-14 2008-10-27 Pf Medicament Utilização do enantiómero (1s, 2r) do milnaciprano para a preparação de um medicamento
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
CA2552064A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
CA2779711C (en) * 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
EP0537915B1 (en) * 1991-09-27 1995-07-12 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
UA56257C2 (ru) 2003-05-15
EP0919236A1 (en) 1999-06-02
AU9128298A (en) 1999-04-12
US6028070A (en) 2000-02-22
CN1270520A (zh) 2000-10-18
WO1999015176A1 (en) 1999-04-01
EA200000349A1 (ru) 2000-10-30
TR200000755T2 (tr) 2000-09-21
CN1146412C (zh) 2004-04-21
HUP0003591A2 (hu) 2002-01-28
HUP0003591A3 (en) 2002-02-28
BR9812357A (pt) 2000-09-12
NZ502810A (en) 2002-03-01
PL339426A1 (en) 2000-12-18
JP2001517627A (ja) 2001-10-09
AU740109B2 (en) 2001-11-01
CA2304115A1 (en) 1999-04-01
NO20001458D0 (no) 2000-03-21
KR20010024218A (ko) 2001-03-26
EA002689B1 (ru) 2002-08-29
NO20001458L (no) 2000-03-21

Similar Documents

Publication Publication Date Title
IL134716A0 (en) Treatment of oppositional defiant disorder
IL134718A0 (en) Treatment of conduct disorder
IL131484A0 (en) Treatment of cardiomyopathy
GB9700899D0 (en) Novel treatment
GB9715295D0 (en) Novel method of treatment
GB9712866D0 (en) Novel method of treatment
PL338726A1 (en) Improved treatment of hides
GB9707693D0 (en) Novel method of treatment
GB9725114D0 (en) Treatment of pruritus
GB9715298D0 (en) Novel method of treatment
GB9715306D0 (en) Novel method of treatment
IL149533A0 (en) Treatment of sle with dehydropiandrosterone
GB2323652B (en) Means of assembly
GB9512124D0 (en) Ammoxidation of propane
GB2327432B (en) Treatment of fabrics
GB9721828D0 (en) Authentication of manufactured items
GB2331514B (en) Effluent treatment
GB9622852D0 (en) Treatment of intimal hyperplasma
GB9701448D0 (en) Methods of treatment
TW337239U (en) Improved structure of an inner footstock
GB9721692D0 (en) Novel treatment
GB9724088D0 (en) Treatment of dyskinesia
EG24157A (en) Novel method of treatment
EG24199A (en) Novel method of treatment
ZA9811524B (en) Treatment of effluent

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees